OUR VISION

Immunosyn’s Corporate Vision: SF-1019 and Beyond

At Immunosyn, we envision ourselves improving the quality of life of millions of people who suffer from painful and debilitating diseases, but every vision must have strategy in order to succeed - what follows is our strategy for achieving this vision:

Our Primary Strategy

• Expand operations and establish a position in the market to be poised for distribution of SF-1019, upon its potential regulatory approval in the appropriate jurisdictions, and/or the distribution of other new products.
• Prepare to cultivate market awareness and acceptance of SF-1019 in the appropriate jurisdictions as a potential first line of defense by mainstream medical practitioners for the treatment of conditions related to Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Diabetic Neuropathy (DN), Diabetic Ulcers (DU), Reflex Sympathetic Dystrophy Syndrome (RSD or RSDS), also known as Complex Regional Pain Syndrome (CRPS), and to educate those affected by these diseases once SF-1019 has been proven to be effective and has received appropriate regulatory approvals.
• Build worldwide sales and distribution channels so that if and when SF-1019, or any other possible Immunosyn products, receive regulatory approval they can be sold and distributed without delay. 
• Develop and execute diligent post sales support to ensure customer satisfaction and safety.

Our Ongoing Strategy

• Identify and analyze potential new cutting edge therapeutics that have been developed by other entities, for which Immunosyn can obtain an exclusive license.  This will be a primary responsibility of our world class Scientific Advisory Board.
• Obtain the exclusive marketing and distribution rights to life enhancing therapeutics.
• Bring likeminded individuals on board whose focus is on educating both the medical community and the patients for which our therapeutics have been developed. 
• Launch a line of yet to be determined prescription veterinary treatments for the health and well being of horses, livestock and companion animals.